Our mandate is to advance knowledge about cancer and other diseases, to improve human health through disease prevention, diagnosis and therapeutic approaches, and realize the social and economic benefits of genome research. We are CAP, DAP and ISO 27001 certified and designed for flexible, efficient, secure, scalable and high-throughput, high-quality analyses. Our state-of-the-art clinical, sequencing, bioinformatics and proteomics platforms are ready to be put to use for your research or clinic.
Our clinical facilities are CAP and DAP certified to offer three distinct panel tests as well as whole genome sequencing.
We offer multiple high quality and high throughput targeted, whole genome, transcriptome and bespoke sequencing services.
We deliver highly specific and sensitive analyses, provide reliable database construction or data deposition support and specialize in customized informatic services.
Sample Submission Requirements
We accept a variety of samples including nucleic acids, blood, fresh or frozen tissues, formalin-fixed/paraffin-embedded (FFPE) tissues, saliva and buccal (cheek) swabs. We also accept fully constructed libraries.
For more information about recommended starting material and plate/tube requirements for sequencing services, please refer to our user guides.
- For best library construction results please submit the recommended amount of starting material or more
- There recommended starting material in our user guides work well for human or mouse derived nucleic acids. Please enquire if you are working with other species.
- The amounts listed in our user guides are the minimum amount of starting material which will result in adequate sequencing results. Please contact us if your material is limiting
For more information please see FAQ.
Terms of Service
Platform services at the GSC are collaborative and are available and accessible to any and all qualified researchers. Collaborative services are billed on a cost recovery, meaning that we charge only the costs of conducting the service. Pricing is based on the scope and type of work requested.
Where warranted due to a collaborator's requirements, we can operate on a fee-for-services basis. We encourage the use of the platform for commercial or service based activity on Terms and Conditions determined by the BC Cancer Technology Development Office. Regardless of the service type, the order of work and delivery of service follow the principles described below.
For all services, the order of work done is determined on a "first in, first on" principle, and we require that all researchers establish a statement of work with us for their activities prior to the submission of any samples. All work is queued in our systems based on the date of sample receipt. Turnaround times may vary widely, based not only on the numbers of samples or other work in the queue but also status of technology development; during times when instrument or systems upgrades are being installed or implemented, turnaround times may be affected while the platform adopts newer, better methods and technology.
Because we operate on a collaborative, cost-recovery basis, we are unable to offer volume discounts for large sample sets or to enable enhanced/faster service with surcharges or premiums.
Also, as a collaborative service provider, we require all collaborators accessing services to acknowledge the work performed by the GSC. Please see acknowledgement and reference policy for these requirements.
Acknowledgement & Reference Policy
In order to gauge our scientific impact we attempt to track our contribution to the wider scientific community. This is done as part of our ongoing support for the activities of our collaborators, as well as to ensure we meet the requirements of both our funding partners and our charter as a non-profit agency. In order to achieve this, we require our collaborators to acknowledge the work performed by the GSC in any or all of the following ways:
- The GSC does not request or require co-authorship on publications when data has been generated through their cost-recovery collaborative service alone, i.e. when no intellectual contribution has been made.
- Where intellectual contributions have been made by the GSC, collaborators are required to discuss potential and pending publications based on these contributions with the relevant GSC scientists or staff to identify appropriate co-authorship.
- At a minimum, acknowledgement of the work of the GSC should be included in peer-reviewed publications. The following sentence can be incorporated into the Acknowledgements section of the article: “The authors wish to acknowledge Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada for [activity]." A full list of funders of infrastructure and research supporting the services accessed can be found on the About Us page.
- In addition, acknowledgements should appear in the text of peer-reviewed publications, for example in the Materials and Methods sections. A suggested sentence for inclusion is: “[Activity] was performed by Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada”.
We would be very pleased to receive notification when collaborators publish papers acknowledging the GSC.
Questions about project design, cost or turnaround time?
We provide access to a diversity of cutting-edge sequencing and bioinformatics tools and techniques and can customize our services for your specific research or clinical projects. Let us help you discover new possibilities by leveraging our expertise in scientific collaboration to design new approaches and technologies specific to your research questions. Cost and turnaround time, as well as the feasibility of meeting a project's needs, are dependent on the type, scope and scale of services that are needed. Consult our FAQ or let us know how we can help—you can provide us with the details of your project or contact our Platform Leaders directly: